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A B S T R A C T
Background: Because of lack of worldwide standardization of inﬂuenza virus surveillance, comparison
between countries of impact of a pandemic is challenging. For that, other approaches to allow
internationally comparative serosurveys are welcome.
Objectives: Here we explore the use of neonatal screening dried blood spots to monitor the trends of the
2009 inﬂuenza A (H1N1) pdm virus by the use of a protein microarray.
Study design: We contacted colleagues from neonatal screening laboratories and asked for their
willingness to participate in a study by testing anonymized neonatal screening bloodspots collected
during the course of the pandemic. In total, 7749 dried blood spots from 13 countries in 5 continents
where analyzed by using a protein microarray containing HA1 recombinant proteins derived from
pandemic inﬂuenza A (H1N1) 2009 as well as seasonal inﬂuenza viruses.
Results: Results conﬁrm the early start of the pandemic with extensive circulation in the US and Canada,
when circulation of the new virus was limited in other parts of the world. The data collected from sites in
Mexico suggested limited circulation of the virus during the early pandemic phase in this country. In
contrast and to our surprise, an increase in seroprevalence early in 2009 was noted in the dataset from
Argentina, suggestive of much more widespread circulation of the novel virus in this country than in
Mexico.
Conclusions: We conclude that this uniform serological testing of samples from a highly standardized
screening system offers an interesting opportunity for monitoring population level attack rates of
widespread diseases outbreaks and pandemics.
ã 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Contents lists available at ScienceDirect
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In April 2009, a novel inﬂuenza A (H1N1) pdm virus emerged
from Mexico, and quickly spread all over the world, causing a
pandemic. It was estimated that the pandemic affected tens of
millions of persons, but such estimates are difﬁcult to obtain [1].
Surveillance across countries is not standardized, making direct
comparison between countries of impacts of a pandemic based on
case detection rates very difﬁcult [2]. Population-based serologi-
cal surveys can be helpful to get a better picture of the attack rate
of an outbreak or widespread epidemic, and comparative analysis
of age-structured seroprevalence data with notiﬁcations based on
clinical parameters has helped determine population impact
across age groups. To set up an active serological surveillance for
inﬂuenza virus, serum samples should be collected on a regular
basis, but this is not done routinely in most countries. As a result,
the ﬁrst population-based serological studies were reported
eight-to-nine months after the initial start of the pandemic [2],
when testing residual sera from diagnostic laboratories provided
valuable information [3,4].
A second challenge when performing serological studies is the
variability between laboratories, when using the gold standard
test methods that employ biological reagents such as animal red
blood cells (in hemagglutination inhibition assays (HAI)) or living
cells (microneutralization test (MNT)) [5]. A review of studies
from individual countries suggested differences in the proportion
of persons with inﬂuenza A (H1N1) pdm cross-reactive antibodies
prior to the pandemic in different countries, but it is difﬁcult to
disentangle test variation from true differences. Evaluation of
such studies in the wake of the 2009 pandemic concluded that
there is a need for more standardized approaches to serosurveys,
including the laboratory testing, to determine the real impact of
the pandemic more easily [6–8].
Dried blood spot (DBS) cards have been used for decades in
neonatal screening [9]. The highly standardized, easy way of
sampling and the stability of the DBS, once dried, are major
advantages of this screening sample method [10]. The use of DBS
for diagnostics is thus expanding, with applications based on
detection of viral genome, antibodies and other molecules such as
antiviral drugs [11,12].
2. Objectives
Here, we explored the possible use of routinely collected dried
blood spot cards from neonatal screening programs for serological
surveillance of inﬂuenza virus by the use of protein microarray
[13].
3. Study design
Following notiﬁcation of the emergence of a novel inﬂuenza
virus strain in humans, we contacted colleagues from neonatal
screening laboratories and asked for their willingness to
participate in a study to monitor the trends of the inﬂuenza A
(H1N1) pdm virus by testing anonymized neonatal screening
bloodspots. In total, 15 laboratories worldwide agreed to
participate. A study protocol was drafted and each participant
checked compliance against local medical ethical rules. Labora-

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































mcontinents (Supplemental Information 1). Participating labora-
tories agreed to collecting 10 randomly selected anonymized DBS
per week, in concordance with policies of local ethical
committees. The collection period differed per country (Table 1).
After collection, DBS were stored at temperature (4 C to room
temperature) and humidity controlled environment, before
76 E. de Bruin et al. / Journal of Clinical Virology 61 (2014) 74–80Table 2
Commercially available recombinant Hemagglutinins (HA1 part) used in this study.
Code Inﬂuenza virus strain Manufacturer
H1–18 A/South Carolina/1/18 (H1N1) Immune Technology Corp.
H1–33 A/WS/33 (H1N1) Immune Technology Corp.
H1–99 A/New Caledonia/20/99 (H1N1) Immune Technology Corp.
H1–07 A/Brisbane/59/2007 (H1N1) Immune Technology Corp
H1–09 A/California/6/2009 (H1N1) Immune Technology Corp.
H2–05 A/Canada/720/05 (H2N2) Immune Technology Corp.
H3–03 A/Wyoming/3/03 (H3N2) Immune Technology Corp.
H3–07 A/Brisbane/10/2007 (H3N2) Immune Technology Corp.
H5–04 A/Vietnam/1194/2004 (H5N1) Immune Technology Corp.
H5–06 A/Turkey/15/2006 (H5N1) Genscript
H5–05 A/Indonesia/5/2005 (H5N1) Genscript
H7–03 A/chicken/Netherlands/1/03 (H7N7) Immune Technology Corp.
H9–99 A/guinea fowl/Hong Kong/WF10/99 (H9N2) Immune Technology Corp.
































































































Fig. 1. Results of HA1 antibody testing of serially diluted serum eluted from DBS
collected before (DBS taken on February 16, 2009) or after the pandemic (DBS taken
on April 27, 2010). Red lines indicate medians. Grey dots (on the right) are DBS
collected within the study before April 2009 and used to calculate the cut-off
(dotted horizontal line).sending them to the RIVM per courier (time for travelling ranged
up to 6 days). Upon arrival at the RIVM the DBS were stored at
20 C until further testing.
3.1. Sampling protocol
All laboratories used ﬁlter paper of comparable absorbance
speciﬁcations (either Whatman 903, Ahlstrom 226 or Toyo Roshi
545) [14]. Incompletely saturated DBS were discarded. In addition,
the ﬁrst 24 weeks of DBS from one of the Mexican laboratories
(Mexico 1, in Supplemental Information 1) were rejected, because
plasma failed to elute from the ﬁlter paper and all sera were
negative when tested on microarray, including seasonal inﬂuenza
virus antigens used as positive controls. From week 26 onwards,
this problem no longer occurred, and the signal from all the
antigens (including the seasonal H1 and H3 types) were stable over
time.
3.2. Control sample
A positive control was made by mixing a human reference
serum positive for inﬂuenza A (H1N1) pdm antibodies (NIBSC, UK)
[15] with 50% packed human red blood cells, followed by spotting
on ﬁlter paper (Whatman 903 ﬁlter paper). After drying, blood
spots of 1/8 in. (containing approximately 1.54 ml (0.17 ml) of
serum [14]) were punched out of the ﬁlter paper and stored at
20 C until further use. One DBS of this positive control was tested
on each tested slide, and was used to correct for test-to-test
variation and for consistency control of assay performance
throughout the study period.
3.3. Preparation and analysis of protein microarrays
The analyses of the protein microarray for the detection of
antibodies to the HA1 part of inﬂuenza virus hemagglutinin have
been described before [9]. For this study we used Oncyte AVID 64-
pad nitrocellulose slides (Grace bio-Labs, Bend, USA). On each 64-
pad, 14 different commercially available recombinant hemaggluti-
nin (HA1-part) proteins (Table 2) were spotted in triplo by the use
of a non-contact spotting machine (Piezorray, Perkin Elmer). Each
DBS was tested in one dilution on a single 64-pad. Before analysis,
DBS were incubated in 40-ml PBS containing 5% Surfact-Amps at
room temperature to release serum from DBS. After one hour, 80 ml
of Blotto-blockingbuffer containing 5% Surfact-Amps (Thermo
Fisher Scientiﬁc Inc., Rockford, USA) was added to the DBS for a
ﬁnal test dilution of approximately 1 in 80. Slides were placed into
a 64-well incubation chamber for analysis and incubated withBlotto-blockingbuffer. After one hour at 37 C, slides were washed
by the use of an automated microplate washer (Biotek, Winooski,
USA) and incubated with 70 ml of eluted serum. After one hour at
37 C, slides were washed and incubated with 70 ml of Blotto-
blockingbuffer containing 5% Surfact-Amps and Dylight 649-
conjugated goat anti-human IgG, fc-fragment speciﬁc (Jackson
ImmunoResearch), diluted 1 in 1300. After one hour at 37 C, slides
were washed, including one extra washing step with water, after
which the slides were dried.
After analysis, the protein microarray slides were scanned by a
ScanArray scanner and spot intensities were quantiﬁed using the
ScanArray Express software (PerkinElmer, Waltham, USA). To
determine a proper cut-off, we used DBS available from Canada
and Sweden from before April 2009. The cut-off was calculated by
the mean ﬂuorescence plus 3 times the standard deviation,
resulting in a cut-off of 30,701 (ﬂuorescence value) for antigen H1–
09 (Fig. 1). Based on this, the smoothed graphical representation of
the data was obtained using a generalized additive model (GAM)
[16,17]. The observations were modeled via the fraction of positive
bloodspots in a week by a logistic regression model, with a smooth
Fig. 2. Proportion of DBS (y-axis) per country per week (x-axis) testing positive for antibodies to HA1 from inﬂuenza A(H1N1) 2009. The red line is a smoothed estimation of
the percentage of positive DBS per week. The dotted red lines mark the 95% conﬁdence interval. Vertical black dotted lines mark the start of the year 2009 or 2010. The vertical
orange and red lines marks the declaration of phase 5 and 6 alert, respectively, by the WHO. The horizontal grey bar within each graph depicts the epidemic period of inﬂuenza
A (H1N1) pdm according to the speciﬁc surveillance data from that country (see Supplemental Information 2). The black V marks the start of inﬂuenza A (H1N1) pdm
vaccination within that country. Seroprevalence studies from the literature are added for comparison marking the period tested by one or a range of triangle-, square-, dot- or
plus-marks. Those marks are linked to each other when more than one period was tested during that study. If a seroprevalence study is added, the name of the ﬁrst author and
the line and mark, which are used to depict the study in the graph, are indicated in the upper left part of the graph.
E. de Bruin et al. / Journal of Clinical Virology 61 (2014) 74–80 77component of time (weeks). The smooth part was deﬁned on the
logit-link scale by a thin-plate regression spline formulation [18].
Estimation of the model was done directly via penalized likelihood
maximization. The degree of smoothness of the spline component
was not a tuning parameter for this model, but was selected by
generalized cross validation [19]. All calculations were done by the
use of R (version 2.14.0) and ﬁtting of GAM models was done by
using the mgcv package in R [20]. Figures were made by the use of
Graph pad Prism 5.0.4.
3.4. Review of surveillance data
Information on the onset of the pandemic wave, the start of
pandemic inﬂuenza vaccination, as well as seroprevalence
estimates were obtained by review of country-speciﬁc surveillancedata from institutional websites and publications, for all countries
except Lebanon. This information is available as Supplemental
Information and summarized in Fig. 2.
4. Results
All data points for antigen H1–09 were collected for individual
countries per week, and percentages of positives were plotted after
smoothing to reduce week to week variation caused by the small
number of weekly samples per site. A ﬁrst comparison of pre- and
post-pandemic DBS from the Netherlands showed low background
values within samples from non-exposed persons, and good
discrimination with reactivity measured in population samples
collected after the pandemic was found in a ﬁnal serum dilution of
80, which was used throughout this study (Fig. 1).
Table 3
Overview of seroprevalence per time period detected in this study.
Country Pre-pandemic, before april 2009 First detections, week 13–24 Pandemic, week 24 until december 2009 December 2009 and onwards
Central Mexico N.T. N.T. 10/226 (4%) 35/277 (13%)
North Mexico 0/129 (0%) 1/107 (1%) 5/196 (3%) N.T.
Argentina N.T. N.T. 52/209 (25%) 55/203 (27%)
United States of America N.T. N.T. 32/210 (15%) 152/310 (49%)
Canada 14/477 (3%) 9/128 (7%) 36/239 (15%) 198/310 (64%)
Japan N.T. N.T. 10/220 (5%) 148/310 (48%)
India N.T. N.T. 10/199 (5%) 21/275 (8%)
The Netherlands N.T. N.T. 9/218 (4%) 119/341 (35%)
Portugal N.T. N.T. 5/209 (2%) 97/270 (36%)
Sweden 3/256 (1%) 3/120 (3%) 18/230 (8%) 126/262 (48%)
Switzerland N.T. 0/20 (0%) 12/230 (5%) 107/387 (28%)
United Kingdom N.T. N.T. 10/220 (5%) 192/348 (55%)
Lebanon 2/106 (2%) 2/87 (2%) 2/144 (1%) N.T.
South Africa N.T. N.T. 2/145 (1%) 3/131 (2%)
Total 19/968 (2%) 15/462 (3%) 213/2895 (7%) 1253/3424 (37%)
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Four countries (the site in Northern Mexico, Canada, Sweden
and Lebanon) started collection of DBS early on, and therefore had
data on reactivity of the H1 2009HA1 antigen for this time period.
The number of samples testing above cut-off for this time period
was 2% (Table 3). There was inﬂuenza virus activity in the northern
hemisphere during this period, but related to seasonal inﬂuenza
virus A (H1 and H3) and B activity. The Swedish inﬂuenza virus
season reached highest incidences from week 51 (2008) to week 10
(2009) and in Canada there was a seasonal peak starting from the
end of 2008 and reached highest incidence at week 9 and 10 of
2009. The end of the seasonal peak within Canada coincided with
the ﬁrst detections of inﬂuenza A (H1N1) pdm virus (Supplemental
Information 2).
4.2. First detections, week 13–14
This period comprise the ﬁrst detections of a novel inﬂuenza
virus in April 2009 until the declaration of the pandemic phase 6 by
the WHO (week 24). The same four countries had data for this
second study period. In Mexico, Lebanon, and Sweden, the
proportion positive samples remained within the 0–3% range,
although visually a slight and temporary elevation was noted in the
data from Sweden. The data from Canada suggested more
widespread infections, reaching on average 7% seropositivity
(Table 3). When reviewing data from inﬂuenza virus surveillance
systems, increased activity was notiﬁed from April onwards in
Mexico and Canada (depicted as grey bars above trend lines in
Fig. 2, and Supplemental Information 2).
4.3. Pandemic period, from WHO phase 6 to December 2009 (week 25–
48)
For this period, data were available for all participating
countries. This time period was chosen because vaccination for
the pandemic strain became available only towards the end of this
time period, and therefore the data mostly reﬂects antibodies
produced through natural infections. Here, the difference in onset
of the pandemic is clearly seen, with increased seroprevalence in
Argentina, Canada and the US. The comparative study suggests
limited circulation of pandemic inﬂuenza during this study period
in all other countries, including Mexico.
4.4. Pandemic period from December onward
During this period, seroprevalence data reﬂect a combination of
natural immunity and vaccine-induced antibodies. Whereavailable, we listed the starting dates of vaccination in Fig. 2. As
our data were anonymized, we were not able to stratify samples
according to vaccination history. The data suggested very limited-
if any- circulation of the virus in South Africa, but clear increase in
seroprevalence in all other countries for which data was available
for this time period.
4.5. Comparison with published seroprevalence data
The measurements from our study were compared with
published literature for the participating countries where available
(Supplemental Information 3), and plotted in Fig. 2. Overall good
agreement between studies was seen despite the use of different
assays, except for two estimates, which were from North Mexico,
and a prepandemic estimate for the UK (Fig. 2 and Supplemental
Information 3). However, data from North Mexico do not overlap in
sampling period, and, the pre-peak within the UK was seen mainly
in England, while DBS from Scotland were tested within this study.
5. Discussion
In this large-scale study, we present data from a comparative
serological study using DBS from ongoing neonatal screening
programs in 13 countries, to compare the evolution of the 2009
inﬂuenza A(H1N1) pandemic using a standardized serological
technique. Our study conﬁrms the early start with extensive
circulation in the US and Canada in spring of 2009, when
circulation of the new virus was limited in other parts of the
world until the pandemic wave towards the end of the year was
observed. The study also showed some interesting differences.
Data collected from sites in Mexico suggested limited circulation of
the virus during the early pandemic phase in this country, which is
in contrast with the hypothesis that the pandemic originated there.
In contrast to the ﬁndings for Mexico and to our surprise, an
increase in seroprevalence early in 2009 was noted in the dataset
from Argentina, suggestive of much more widespread circulation
of the novel virus in this country compared to Mexico. The
newborn screening quality assurance program [14] used in this
study is very standardized and used within 448 newborn screening
laboratories in 61 counties (numbers for 2009). This screening
program is not biased by active case ﬁnding or media attention, and
the comparison of outcomes of our study with those from
published serosurveys showed excellent agreement (Fig. 2).
Therefore, we consider this result reliable. A question is how to
explain this observation. The discrepancy between seroprevalence
and presumed widespread cases cannot be explained by sampling,
as two of the sites participating in our study were located in central
Mexico. Alternatively, the number of cases may not have been high
E. de Bruin et al. / Journal of Clinical Virology 61 (2014) 74–80 79enough to cause a detectable increase in seropositivity. In the
Netherlands, active case ﬁnding caused a pre-peak, which was not
reﬂected in ILI sentinel detections or this study. The same might
have happened in Mexico, suggesting that impact of the epidemic
in Mexico was overestimated by active case ﬁnding. Initial cases
diagnosed with inﬂuenza A(H1N1) 2009 were traced to Mexico as
the most likely region where infection was acquired, and reports of
widespread disease suggested a large outbreak. The metropole
Mexico city could have acted as a hub for dispersal of inﬂuenza
viruses from imported cases, similar to what happened in the US
and UK.
The impact of the pandemic was not observed everywhere
during this study period. In India only a small rise in positive
individuals from week 2 to 12 in 2010 was observed. The number of
laboratory conﬁrmed patients reportedly increased in the months
September and October 2009 in the Andhra Pradesh province
(Supplemental Information 2), but this was the only participating
country that does not have a clear seasonal pattern of inﬂuenza
virus [21]. During the 2009 season within South Africa, seasonal H3
and (H1N1) pdm inﬂuenza virus were both detected. Unfortunate-
ly, collecting DBS in South Africa stopped just before the second
wave during the 2010 season.
While the approach presented here could be an interesting
addition to case based or virological surveillance, there are
disadvantages. During primary infections the three Ig classes
can be detected within 10–14 days, whereas IgG level peaks 4–6
weeks after infection [22]. For that reason, serological studies are
delayed in detection of infection compared to virus detection
methods. Within this study, maternal IgG antibodies are measured.
The antibody repertoire of the child in the ﬁrst 3–12 months is
dependent on the mother's accumulated immunological experi-
ence [23,24]. Thus, the antibodies detected through our approach
result from the mother's history of inﬂuenza virus infections and
vaccinations. Within this study, another delay comes from the time
between taking DBS and birth of the infant. In the Netherlands,
neonatal screening blood samples are taken 72–168 h after birth.
Because of increased morbidity and mortality from inﬂuenza
virus infection, vaccination of pregnant women is recommended,
but the policy for inﬂuenza virus vaccination differs per country
[25]. During the pandemic, pregnant women were listed among
the group at risk for severe inﬂuenza, and the numbers of infected
persons might be overestimated by our approach. We were not
able to ﬁnd weekly estimates of the vaccination rate for pregnant
women in the different countries, and the steep increases in
seroprevalence in countries with active vaccination most likely
reﬂects vaccine induced antibodies, although vaccination coincid-
ed with the onset of the pandemic wave in some countries.
Age dependent prevalence of antibodies to the inﬂuenza A
(H1N1) pdm virus has been described by several publications,
though ﬁndings differ among the published studies for the age
group presented in this study. Some studies show higher incidence
of cross reactive antibodies within the age group of approximately
18–29 years old [4,26,27], whereas other studies did not show this
difference [3,28]. Although we cannot completely rule out biases
due to differences between countries in average childbearing age,
we found a remarkable agreement with results from published
serosurveys from individual countries at speciﬁc time points, as
indicated in Fig. 2. Therefore, we do not expect major inﬂuence of
the sampling on the study outcomes.
We cannot rule out differences in assay performance for
samples from different countries. Because of low volumes of serum
per individual, it was not possible to do more tests on the DBS, such
as an elution control. Nevertheless, we did test median signals for
the seasonal antigens H1 and H3 that looked stable over time. DBS
were stored at 20 C for a long period before testing. Because of
lack of good reference material early in 2009 to test stability duringstorage it was not tested whether this might have inﬂuenced the
height of the signal. However, stability of DBS is normally very good
especially at 20 C [12].
In conclusion, this standardized serological testing of samples
from a highly standardized screening system offers an interesting
opportunity for monitoring population level attack rates of
widespread diseases outbreaks and pandemics.
Funding:
Microarray development was supported by strategic research
from the RIVM (grant number S/340004/01), and by the Impulse
Veterinary Avian Inﬂuenza Research in The Netherlands, pro-
gramme of the Economic Structure Enhancement Fund. The
funding sources had no role in the writing of the manuscript or
the decisions made for this study.
Competing interest:
The authors declare no competing interests or conﬂict of
interest.
Ethical approval:
Each participant checked compliance against local medical
ethical rules. For the DBS from Japan, ethical approval was given by
the Institutional Review Board of Sapporo City Institute of Public
Health Judgment's (reference number 09-010). NYS DOH Institu-
tional Review board approval was obtained for the DBS from the
United States of America (protocol number #09-045).
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.jcv.2014.06.020.
References
[1] Girard MP, Tam JS, Assossou OM, Kieny MP. The 2009 A (H1N1) inﬂuenza virus
pandemic: a review. Vaccine 2010;28(31):4895–902.
[2] Briand S, Mounts A, Chamberland M. Challenges of global surveillance during
an inﬂuenza pandemic. Public Health 2011;125(5):247–56.
[3] Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, et al. Cross-reactive
antibody responses to the 2009 pandemic H1N1 inﬂuenza virus. N Engl J Med
2009;361(20):1945–52.
[4] Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M. Incidence
of 2009 pandemic inﬂuenza A H1N1 infection in England: a cross-sectional
serological study. Lancet 2010;375(9720):1100–8.
[5] Wood JM, Major D, Heath A, Newman RW, Hoschler K, Stephenson I, et al.
Reproducibility of serology assays for pandemic inﬂuenza H1N1: collaborative
study to evaluate a candidate WHO international standard. Vaccine 2012;30
(2):210–7.
[6] LaurieKL, HustonP, Riley S,Katz JM, WillisonDJ,TamJS, etal. Inﬂuenzaserological
studies to inform public health action: best practices to optimise timing, quality
and reporting. Inﬂuenza Other Respir Viruses 2013;7(2):211–24.
[7] Broberg E, Nicoll A, Amato-Gauci A. Seroprevalence to inﬂuenza A(H1N1) 2009
virus?–where are we?. Clin Vaccine Immunol 2011;18(8):1205–12.
[8] Stephenson I, Heath A, Major D, Newman RW, Hoschler K, Junzi W, et al.
Reproducibility of serologic assays for inﬂuenza virus A (H5N1). Emerg Infect
Dis 2009;15(8):1252–9.
[9] Sahai I, Marsden D. Newborn screening. Crit Rev Clin Lab Sci 2009;46(2):55–82.
[10] Mei JV, Zobel SD, Hall EM, De Jesus VR, Adam BW, Hannon WH. Performance
properties of ﬁlter paper devices for whole blood collection. Bioanalysis
2010;2(8):1397–403.
[11] Snijdewind IJ, van Kampen JJ, Fraaij PL, van der Ende ME, Osterhaus AD, Gruters
RA. Current and future applications of dried blood spots in viral disease
management. Antivir Res 2012;93(3):309–21.
[12] Bertagnolio S, Parkin NT, Jordan M, Brooks J, Garcia-Lerma JG. Dried blood
spots for HIV-1 drug resistance and viral load testing: a review of current
knowledge and WHO efforts for global HIV drug resistance surveillance. AIDS
Rev 2010;12(4):195–208.
[13] Koopmans M, de Bruin E, Godeke GJ, Friesema I, van Gageldonk R, Schipper
M, et al. Proﬁling of humoral immune responses to inﬂuenza viruses by using
protein microarray. Clin Microbiol Infect 2012;18(8):797–807.
80 E. de Bruin et al. / Journal of Clinical Virology 61 (2014) 74–80[14] Anonymous. Newborn Screening Quality Assurance Program: Centers for
Disease Control and Prevention; February 2010: 2010.
[15] Control NIBSC. Inﬂuenza Reagent Candidate International Standard for
Antibody to Inﬂuenza H1N1pdm Virus. NIBSC code 09/194 Version 20. Ridge,
United Kingdom: Health Protection Agency; 2010.
[16] Wood SN. Generalized additive models: an introduction with R. Chapman and
Hall/CRC; 2006.
[17] Wood SN. Fast stable restricted maximum likelihood and marginal likelihood
estimation of semiparametric generalized linear models. J R Stat Soc: Series B
(Statistical Methodology) 2011;73(1):3–36.
[18] Wood SN. Thin plate regression splines. J R Stat Soc: Series B (Statistical
Methodology) 2003;65(1):95–114.
[19] Wood SN. Stable and efﬁcient multiple smoothing parameter estimation for
generalized additive models. J Am Stat Assoc 2004;99:673–86.
[20] R Development Core Team. R: A language and environment for
statistical computing. Vienna, Austria: R Foundation for Statistical
Computing; 2011.
[21] Broor S, Krishnan A, Roy DS, Dhakad S, Kaushik S, Mir MA, et al. Dynamic
patterns of circulating seasonal and pandemic A(H1N1)pdm09 inﬂuenza
viruses from 2007–2010 in and around Delhi, India. PLoS One 2012;7(1):
e29129.[22] Tamura S, Kurata T. Defense mechanisms against inﬂuenza virus infection in
the respiratory tract mucosa. Jpn J Infect Dis 2004;57(6):236–47.
[23] Puck JM, Glezen WP, Frank AL, Six HR. Protection of infants from infection with
inﬂuenza A virus by transplacentally acquired antibody. J Infect Dis 1980;142
(6):844–9.
[24] Zinkernagel Maternal antibodies RM. childhood infections, and autoimmune
diseases. The N Engl J Med 2001;345(18):1331–5.
[25] Mak TK, Mangtani P, Leese J, Watson JM, Pfeifer D. Inﬂuenza vaccination in
pregnancy: current evidence and selected national policies. Lancet Infect Dis
2008;8(1):44–52.
[26] Dudareva S, Schweiger B, Thamm M, Höhle M, Stark K, Krause G, et al.
Prevalence of antibodies to 2009 pandemic inﬂuenza A (H1N1) virus in
German adult population in pre-and post-pandemic period. PLoS One 2011;6
(6):e21340.
[27] Maltezou HC, Katerelos P, Mavrouli M, Lourida A, Routsias JG, Spanakis N, et al.
Seroepidemiological study of pandemeic inﬂuenza H1N1 following the 2009–
2010 wave in Greece. Vaccine 2011;29:6664–9.
[28] Ikonen N, Strengell M, Kinnunen L, Österlund P, Pirhonen J, Broman M, et al.
High frequency of cross-reacting antibodies against 2009 pandemic inﬂuenza
A(H1N1) virus among the elderly in Finland. Eurosurveillance 2010;15
(5):19478.
